# US 10,869,842 B1 · Transdermal delivery of pharmaceutical agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,842 B1
- Document ID: US10869842B1
- Status: Granted
- Kind: B1
- Application number: 15/698,536
- Filed: 2017-09-07
- Granted: 2020-12-22
- Earliest claimed: 2016-09-07
- Applicants: David P Summers
- Inventors: David P Summers
- Web page: https://patentgrep.com/patent/US10869842B1

## CPC

- A61K 9/7084: {Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches}
- A61K 9/7092: {Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs}
- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/7038: {Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of administering a pharmaceutical agent to the circulatory system through the skin of a mammal may include the steps of loading a pharmaceutical agent in a transdermal patch, applying the transdermal patch to the skin of the mammal and releasing the pharmaceutical agent into the circulatory system at a rate of at least 0.001 micrograms per hour up to 50.0 micrograms per hour per kilogram of bodyweight of the mammal. The drug delivery system may comprise a transdermal patch loaded with the pharmaceutical agent. The patch may include a porous membrane and an outer impermeable cover defining a cavity therebetween. A plurality of drug delivery layers may be disposed between the porous membrane and the impermeable cover. A lipophilic/hydrophilic suspension may be disposed between the drug delivery layers.

## Claims

### Claim 1

A drug delivery system comprising:
a) a transdermal patch for administering a pharmaceutical agent through the skin of a patient;
b) said patch including a porous membrane and an outer impermeable cover defining a cavity therebetween;
c) a layer of semi-porous adhesive applied to a bottom surface of said porous membrane;
d) a plurality of drug delivery tapes disposed in said cavity in vertical spaced layers relative to one another;
e) a plurality of micro-dots containing said pharmaceutical agent imprinted on each said plurality of drug delivery tapes; and
f) a layer of lipophilic or hydrophilic suspension disposed between said layers of said plurality of drug delivery tapes.

### Claim 2 (depends on 1)

The drug delivery system of claim 1 wherein said pharmaceutical agent is released at a rate of at least 0.001 micrograms per hour up to 50.0 micrograms per hour per kilogram of bodyweight of the patient.

### Claim 3 (depends on 1)

The drug delivery system of claim 1 wherein said pharmaceutical agent is released at a rate of 20 micrograms per hour per kilogram bodyweight of the patient.

### Claim 4 (depends on 1)

The drug delivery system of claim 1 wherein said porous membrane includes a plurality of apertures.

### Claim 5 (depends on 1)

The drug delivery system of claim 1 wherein said pharmaceutical agent comprises cannabis THC.

### Claim 6 (depends on 1)

The drug delivery system of claim 1 wherein said pharmaceutical agent comprises cannabinols.

### Claim 7 (depends on 1)

The drug delivery system of claim 1 wherein said pharmaceutical agent comprises a liposomal prostaglandin, prostaglandin derivative, prostaglandin prodrug, or mixture thereof.

### Claim 8 (depends on 1)

The drug delivery system of claim 1 wherein said pharmaceutical agent comprises a lipophilic fatty acid.

### Claim 9 (depends on 1)

The drug delivery system of claim 1 further including a biocompatible membrane overlaying said plurality of drug delivery tapes.

### Claim 10 (depends on 1)

The drug delivery system of claim 1 further including a removable liner overlaying said semi-porous adhesive layer.

### Claim 11 (depends on 9)

The drug delivery system of claim 9 wherein said pharmaceutical agent comprises a liposomal prostaglandin, prostaglandin derivative, prostaglandin prodrug, or mixture thereof.

### Claim 12 (depends on 9)

The delivery system of claim 9 wherein said pharmaceutical agent comprises cannabis THC, cannabinols, or prostaglandins in liposomal or raw form.